This drug is mainly indicated for ovarian cancer, fallopian tube cancer, peritoneal cancer, pancreatic cancer, and prostate cancer with hereditary or somatic BRCA1 or BRCA2 mutation [1, 2]. This evidence concerns the gene BRCA1 and ovarian cancer.